256 related articles for article (PubMed ID: 1336492)
1. Frequent occurrence of p53 gene mutations in uterine cancers at advanced clinical stage and with aggressive histological phenotypes.
Tsuda H; Hirohashi S
Jpn J Cancer Res; 1992 Nov; 83(11):1184-91. PubMed ID: 1336492
[TBL] [Abstract][Full Text] [Related]
2. Pathogenetic significance of p53 and c-Ki-ras gene mutations and human papillomavirus DNA integration in adenocarcinoma of the uterine cervix and uterine isthmus.
Jiko K; Tsuda H; Sato S; Hirohashi S
Int J Cancer; 1994 Dec; 59(5):601-6. PubMed ID: 7960232
[TBL] [Abstract][Full Text] [Related]
3. Alterations of the p53 gene in human primary cervical carcinoma with and without human papillomavirus infection.
Fujita M; Inoue M; Tanizawa O; Iwamoto S; Enomoto T
Cancer Res; 1992 Oct; 52(19):5323-8. PubMed ID: 1327506
[TBL] [Abstract][Full Text] [Related]
4. Mutations of p53 and human papillomavirus infection in cervical carcinoma.
Paquette RL; Lee YY; Wilczynski SP; Karmakar A; Kizaki M; Miller CW; Koeffler HP
Cancer; 1993 Aug; 72(4):1272-80. PubMed ID: 8393371
[TBL] [Abstract][Full Text] [Related]
5. Presence of p53 mutation in human cervical carcinomas associated with HPV-33 infection.
Lo KW; Mok CH; Chung G; Huang DP; Wong F; Chan M; Lee JC; Tsao SW
Anticancer Res; 1992; 12(6B):1989-94. PubMed ID: 1363512
[TBL] [Abstract][Full Text] [Related]
6. Correlation between human papillomavirus positivity and p53 gene overexpression in adenocarcinoma of the uterine cervix.
Uchiyama M; Iwasaka T; Matsuo N; Hachisuga T; Mori M; Sugimori H
Gynecol Oncol; 1997 Apr; 65(1):23-9. PubMed ID: 9103386
[TBL] [Abstract][Full Text] [Related]
7. p53 gene mutations and MDM2 amplification are uncommon in primary carcinomas of the uterine cervix.
Kessis TD; Slebos RJ; Han SM; Shah K; Bosch XF; Muñoz N; Hedrick L; Cho KR
Am J Pathol; 1993 Nov; 143(5):1398-405. PubMed ID: 8238255
[TBL] [Abstract][Full Text] [Related]
8. Human papillomavirus DNA and p53 status in stage IB bulky cervical cancer.
Chen CA; Chen TM; Wu CC; Chang CF; Hsieh CY
J Cancer Res Clin Oncol; 1994; 120(11):678-82. PubMed ID: 7962045
[TBL] [Abstract][Full Text] [Related]
9. p53 mutation and MDM2 amplification are rare even in human papillomavirus-negative cervical carcinomas.
Ikenberg H; Matthay K; Schmitt B; Bauknecht T; Kiechle-Schwarz M; Göppinger A; Pfleiderer A
Cancer; 1995 Jul; 76(1):57-66. PubMed ID: 8630877
[TBL] [Abstract][Full Text] [Related]
10. Correlation between HPV positivity and state of the p53 gene in cervical carcinoma cell lines.
Iwasaka T; Oh-uchida M; Matsuo N; Yokoyama M; Fukuda K; Hara K; Fukuyama K; Hori K; Sugimori H
Gynecol Oncol; 1993 Jan; 48(1):104-9. PubMed ID: 8380785
[TBL] [Abstract][Full Text] [Related]
11. The state of the p53 gene in human papillomavirus (HPV)-positive and HPV-negative genital precancer lesions and carcinomas as determined by single-strand conformation polymorphism analysis and sequencing.
Kurvinen K; Tervahauta A; Syrjänen S; Chang F; Syrjänen K
Anticancer Res; 1994; 14(1A):177-81. PubMed ID: 8166446
[TBL] [Abstract][Full Text] [Related]
12. Uterine cervix adenocarcinoma with both human papillomavirus type 18 and tumor suppressor gene p53 mutation from a woman having an intact hymen.
Craigo J; Hopkins M; DeLucia A
Gynecol Oncol; 1995 Dec; 59(3):423-6. PubMed ID: 8522268
[TBL] [Abstract][Full Text] [Related]
13. Well-differentiated villoglandular adenocarcinoma of the uterine cervix: oncogene/tumor suppressor gene alterations and human papillomavirus genotyping.
Jones MW; Kounelis S; Papadaki H; Bakker A; Swalsky PA; Woods J; Finkelstein SD
Int J Gynecol Pathol; 2000 Apr; 19(2):110-7. PubMed ID: 10782406
[TBL] [Abstract][Full Text] [Related]
14. The role of p53 inactivation in human cervical cell carcinoma development.
Miwa K; Miyamoto S; Kato H; Imamura T; Nishida M; Yoshikawa Y; Nagata Y; Wake N
Br J Cancer; 1995 Feb; 71(2):219-26. PubMed ID: 7841033
[TBL] [Abstract][Full Text] [Related]
15. Detection of human papillomavirus DNA and p53 gene mutations in human prostate cancer.
Suzuki H; Komiya A; Aida S; Ito H; Yatani R; Shimazaki J
Prostate; 1996 May; 28(5):318-24. PubMed ID: 8610059
[TBL] [Abstract][Full Text] [Related]
16. Alterations of the p53 tumor suppressor gene and its association with activation of the c-K-ras-2 protooncogene in premalignant and malignant lesions of the human uterine endometrium.
Enomoto T; Fujita M; Inoue M; Rice JM; Nakajima R; Tanizawa O; Nomura T
Cancer Res; 1993 Apr; 53(8):1883-8. PubMed ID: 8385572
[TBL] [Abstract][Full Text] [Related]
17. Detection of p53 gene mutations in human ovarian and endometrial cancers by polymerase chain reaction-single strand conformation polymorphism analysis.
Naito M; Satake M; Sakai E; Hirano Y; Tsuchida N; Kanzaki H; Ito Y; Mori T
Jpn J Cancer Res; 1992 Oct; 83(10):1030-6. PubMed ID: 1333465
[TBL] [Abstract][Full Text] [Related]
18. The effects of p53 status and human papillomavirus infection on the clinical outcome of patients with stage IIIB cervical carcinoma treated with radiation therapy alone.
Ishikawa H; Mitsuhashi N; Sakurai H; Maebayashi K; Niibe H
Cancer; 2001 Jan; 91(1):80-9. PubMed ID: 11148563
[TBL] [Abstract][Full Text] [Related]
19. p53 mutations in cervical carcinogenesis--low frequency and lack of correlation with human papillomavirus status.
Busby-Earle RM; Steel CM; Williams AR; Cohen B; Bird CC
Br J Cancer; 1994 Apr; 69(4):732-7. PubMed ID: 8142262
[TBL] [Abstract][Full Text] [Related]
20. The status of human papillomavirus and tumor suppressor genes p53 and p16 in carcinomas of uterine cervix from India.
Munirajan AK; Kannan K; Bhuvarahamurthy V; Ishida I; Fujinaga K; Tsuchida N; Shanmugam G
Gynecol Oncol; 1998 Jun; 69(3):205-9. PubMed ID: 9648588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
